4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Viridian Therapeutics, Inc. (VRDN) operates in the Biotechnology industry and is headquartered in Waltham, United States with about 252 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, VRDN reported $71M in revenue and ($343M) in net income.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Interactive charts & full statements → Open the VRDN valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $71M | $0M | $0M | $2M | — |
| Operating Income (EBIT) | ($363M) | ($299M) | ($254M) | ($134M) | — |
| Net Income | ($343M) | ($270M) | ($238M) | ($130M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $71M | $0M | $0M |
| Operating Income (EBIT) | ($116M) | ($123M) | ($40M) | ($107M) | ($94M) |
| Net Income | ($105M) | ($120M) | ($35M) | ($101M) | ($87M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $899M | $742M | $490M | $435M | — |
| Total Liabilities | $177M | $71M | $48M | $40M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VRDN viewer.
About TickerBase · Data methodology & sources